Welcome to Seacross Pharmaceuticals Ltd.
中文
|
English
Home
About us
>
Seacross
Milestone
News
Plant Profile
>
Overview
Manufacturing Process
Capacity
Logistics & Supply chain
Quality System
>
Quality Assurance
Quality Control
Validation Management
Pharmacovigilance
Products
>
Oncology Injectable
Other Product 1
Other Product 2
Research & Development
>
Chemicals
Biologics
Business Development
>
International Presence
In & Out-Licensing
Contract Development and Manufacturing
Contact
+44 (0)20 8731 5273
Home
About us
Seacross
Milestone
News
Plant Profile
Overview
Manufacturing Process
Capacity
Logistics & Supply chain
Quality System
Quality Assurance
Quality Control
Validation Management
Pharmacovigilance
Products
Oncology Injectable
Other Product 1
Other Product 2
Research & Development
Chemicals
Biologics
Business Development
International Presence
In & Out-Licensing
Contract Development and Manufacturing
Contact
News
MHRA Approval of Product Azacitidine in UK
02.06. 2020
On April 24th, 2020, Seacross Pharma’s Azacitidine for injection was officially approved for the ma…
detail>>
Product launch conference of Azacitidine for injection（“HUIXIN”）in China
03.01. 2020
On September 29, 2019, Huiyu Pharma’s Azacitidine for injection was officially approved for the ma…
detail>>
Huiyu Pharmaceutical (Parent Company of Seacross Pharmaceuticals) Won “Leading Innovation Enterprise Award”
05.12. 2019
On November 10, “2019 China-Japan Advanced Medical and New Drug R & D Summit Forum and Achievement …
detail>>
Participation at CPHI, Frankfurt 2019
12.11. 2019
Under the leadership of the Chairman Mr. Zhao Ding, Seacross attended the CPHI held in Frankfurt fr…
detail>>
Azacitidine of Huiyu Pharma approved as the “first generic” by China FDA.
15.10. 2019
On September 29, 2019, the China FDA issued a notice on the drug approval document, indicating that…
detail>>
Congratulations to Huiyu Pharma on successful completion of GMP re-inspection conducted by CFAD
10.09. 2019
A group of experts from Sichuan Food and Drug Administration GMP certification evaluation center ca…
detail>>
Seacross Pharmaceuticals （a Huiyu subsidiary） was awarded the Best Injectable Oncology Therapeutics Manufacturer 2019 by Global Health & Pharma (GHP)
30.08. 2019
We are delighted to announce that Seacross Pharmaceuticals (a Huiyu subsidiary) was awarded the best…
detail>>
Product launch in Georgia 07.11.2016
07.11. 2016
Seacross Pharmaceuticals is delighted to announce the launch of Irinotecan 20mg/ml in Georgia ! …
detail>>
< prev
1
2
next >
© Copyright - Clinico fusce blandit sapien eu
